- Home
- ICMB vs KPTI Comparison
ICMB vs KPTI Comparison
Compare ICMB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICMB
- KPTI
- Stock Information
- Founded
- ICMB 2012
- KPTI 2008
- Country
- ICMB United States
- KPTI United States
- Employees
- ICMB N/A
- KPTI N/A
- Industry
- ICMB Finance: Consumer Services
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- ICMB Finance
- KPTI Health Care
- Exchange
- ICMB Nasdaq
- KPTI Nasdaq
- Market Cap
- ICMB 40.6M
- KPTI 44.5M
- IPO Year
- ICMB N/A
- KPTI 2013
- Fundamental
- Price
- ICMB $2.72
- KPTI $5.92
- Analyst Decision
- ICMB
- KPTI Buy
- Analyst Count
- ICMB 0
- KPTI 6
- Target Price
- ICMB N/A
- KPTI $39.80
- AVG Volume (30 Days)
- ICMB 28.0K
- KPTI 221.8K
- Earning Date
- ICMB 08-12-2025
- KPTI 08-11-2025
- Dividend Yield
- ICMB 17.65%
- KPTI N/A
- EPS Growth
- ICMB N/A
- KPTI N/A
- EPS
- ICMB 0.93
- KPTI N/A
- Revenue
- ICMB $20,422,069.00
- KPTI $137,269,000.00
- Revenue This Year
- ICMB N/A
- KPTI $2.18
- Revenue Next Year
- ICMB N/A
- KPTI $11.28
- P/E Ratio
- ICMB $2.93
- KPTI N/A
- Revenue Growth
- ICMB N/A
- KPTI N/A
- 52 Week Low
- ICMB $2.46
- KPTI $3.51
- 52 Week High
- ICMB $3.47
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- ICMB 43.65
- KPTI 72.07
- Support Level
- ICMB $2.60
- KPTI $3.65
- Resistance Level
- ICMB $2.71
- KPTI $4.35
- Average True Range (ATR)
- ICMB 0.09
- KPTI 0.50
- MACD
- ICMB -0.01
- KPTI 0.17
- Stochastic Oscillator
- ICMB 54.05
- KPTI 70.06
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.